EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A new genetic diagnosis strategy for paroxysmal kinesigenic dyskinesia: Targeted high‐throughput detection of PRRT2 gene c.649 locus

Min Wen, Hui Huang, Fei Huang, Ru Xu, Jing Zhang, Jia-Geng Fan, Jun Zeng, Kai-Wen Jiang, Ding Liu, Hua-Lin Huang, Qing-Nan He iD

Molecular Genetics & Genomic Medicine · 2024

DOI: 10.1002/mgg3.2469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Genetics & Genomic Medicine, 2024. Verfasst von Min Wen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Membrane Proteins, Nerve Tissue Proteins, Dystonia, Genetic Testing. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Scientific research program of Hunan Provincial Health Commission, the Science and Technology Innovation Program of Hunan Province, Fundamental Research Funds for Central Universities of the Central South University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paroxysmal kinesigenic dyskinesia (PKD) is the most prevalent kind type of paroxysmal Dyskinesia, characterized by recurrent and transient episodes of involuntary movements. Most PKD cases were attributed to the proline‐rich transmembrane protein 2 ( PRRT2 ) gene, in which the c.649 region is a hotspot for known mutations. Even though some patients with PKD have been genetically diagnosed using whole‐exome sequencing (WES) and Sanger sequencing, there are still cases of missed diagnoses due to the limitations of sequencing technology and analytic methods on throughput.

Methods

Patients meeting the diagnosis criteria of PKD with negative results of PRRT2 ‐Sanger sequencing and WES were included in this study. Mutation screening and targeted high‐throughput sequencing were performed to analyze and verify the sequencing results of the potential mutations.

Results

Six patients with PKD with high mutation ratios of c.649dupC were screened using our targeted high‐throughput sequencing from 26 PKD patients with negative results of PRRT2 ‐Sanger sequencing and WES (frequency = 23.1%), which compensated for the comparatively shallow sequencing depth and statistical flaws in this region. Compared with the local normal population and other patients with PKD, the mutation ratios of c.649dupC of these six patients with PKD were much higher and also had truncated protein structures and differentially altered mRNA expression.

Conclusion

Based on the above studies, we emphasize the routine targeted high‐throughput sequencing of the c.649 site in the PRRT2 gene in so‐called genetic‐testing‐negative patients with PKD, and manually calculate the deletion and duplication mutations depth and ratios to lower the rate of clinical misdiagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane ProteinsNerve Tissue ProteinsDystoniaGenetic TestingHumansFemaleMaleChildAdolescentAdultHigh-Throughput Nucleotide SequencingMutationChild, PreschoolExome Sequencing

Stichwörter der Autor:innen

PRRT2c.649 locusparoxysmal kinesigenic dyskinesiatargeted high‐throughput detection

Substanzen

PRRT2 protein, humanMembrane ProteinsNerve Tissue Proteins

Autor:innen und Institutionen

  • Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Medical Genetics, Hunan Province Clinical Research Center for Genetic Birth Defects and Rare Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Reproductive Medicine Center, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Hangzhou Xiangyin Medical Laboratory, Hangzhou, Zhejiang, China.
  • Department of Neurology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

ORCID-Profile: Qing-Nan He

Förderung

  • the Scientific research program of Hunan Provincial Health Commission
  • the Science and Technology Innovation Program of Hunan Province
  • Fundamental Research Funds for Central Universities of the Central South University
  • the National Key Research and Development Program of China

Zitieren

APA

Wen, M., Huang, H., Huang, F., Xu, R., Zhang, J., Fan, J. G., Zeng, J., Jiang, K. W., Liu, D., Huang, H. L., & He, Q. N. (2024). A new genetic diagnosis strategy for paroxysmal kinesigenic dyskinesia: Targeted high‐throughput detection of PRRT2 gene c.649 locus. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.2469

Vancouver

Wen M, Huang H, Huang F, Xu R, Zhang J, Fan JG, et al. A new genetic diagnosis strategy for paroxysmal kinesigenic dyskinesia: Targeted high‐throughput detection of PRRT2 gene c.649 locus. Molecular Genetics & Genomic Medicine. 2024. doi:10.1002/mgg3.2469

BibTeX
@article{Wen2024,
  author = {Wen, Min and Huang, Hui and Huang, Fei and Xu, Ru and Zhang, Jing and Fan, Jia-Geng and Zeng, Jun and Jiang, Kai-Wen and Liu, Ding and Huang, Hua-Lin and He, Qing-Nan},
  title = {A new genetic diagnosis strategy for paroxysmal kinesigenic dyskinesia: Targeted high‐throughput detection of PRRT2 gene c.649 locus},
  journal = {Molecular Genetics & Genomic Medicine},
  year = {2024},
  doi = {10.1002/mgg3.2469}
}
Kostenlos starten →